Icalcaprant

DB21651InvestigationalSmall molecule

Icalcaprant is a small molecule drug. The usage of the INN stem '-caprant' in the name indicates that Icalcaprant is a kappa-opioid receptor (KOR) antagonist. Icalcaprant is under investigation in... Icalcaprant is under investigation in clinical trial NCT06696755 (A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder).

Mechanism: Pharmacologically active on Kappa-type opioid receptor
Curator reviewed
Formula / weight: C₂₃H₂₆N₄O₃ · 406.486 g/mol (avg)
Code names: ABBV-1354 · CVL-354 · PF-06874354

Resolves to

Compound

UNIIGNR4JZG668CAS2227384-17-8ChEMBLCHEMBL5314519ChEBI759223PubChem134540598

Structure

InChIKeyOBDLEFCGVHQDFR-NRFANRHFSA-NSMILESCOC1=NN(C)C=C1[C@@H]1CCCN1CC1=CC=C(OC2=CC=C(C=C2)C(N)=O)C=C1

Targets

P41145OPRK1

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Icalcaprant, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account